Modulation of arabinosylcytosine metabolism during leukemia therapy.
Gandhi
V
V
Department of Clinical Investigation, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
Estey
E
E
Plunkett
W
W
D000970:Antineoplastic Agents / Q000494:pharmacology; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism; D001711:Biotransformation; D003561:Cytarabine / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism; D014740:Vidarabine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D014740:Vidarabine; C024352:fludarabine